ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. reported that ENDRA Life Sciences filed a Form S-4 registration statement on October 2, 2026, relating to the proposed merger under the June 25, 2026 Agreement and Plan of Merger. Under the proposed structure, Kruger Merger Sub LLC, an ENDRA subsidiary, would merge into Noble Africa LLC, an ASP Isotopes subsidiary, with Noble Africa surviving as a direct, wholly owned subsidiary of ENDRA.
The proposed merger is subject to satisfaction or waiver of the conditions in the merger agreement. ENDRA’s S-4 contains a proxy statement and prospectus and includes information about Renergen, another ASP Isotopes subsidiary.
ASP Isotopes Inc. director Robert John Andrew Ryan purchased 15,000 shares of common stock at a weighted average price of $2.68 per share. The footnote says the shares were purchased in multiple transactions at prices from $2.65 to $2.68, inclusive. His reported direct holdings after the purchase were 675,222 shares. No Rule 10b5-1 plan is reported.
ASP Isotopes Inc. director Robert John Andrew Ryan purchased 8,000 shares of common stock at a weighted average price of $2.70 per share. Ryan directly held 660,222 shares following the transaction. No Rule 10b5-1 plan is reported.
ASP Isotopes, Inc. (ASPI) director Todd Wider filed a notice of proposed sale of 200,000 common shares through J.P. Morgan Securities LLC, with an aggregate market value listed as $590,000. The notice lists compensation as the acquisition basis for four common-share lots. It also reports sales of 50,000 shares on June 29 and 50,000 shares on June 30, 2026.
ASP Isotopes Inc. (ASPI) reported that its COO, Robert Ainscow, sold 8,438 shares of common stock in an open-market transaction at a weighted average price of $4.292 per share, with prices ranging from $4.185 to $4.39. According to the disclosure, this was a "sell to cover" transaction executed under a Rule 10b5-1 trading plan adopted on June 9, 2025 to cover tax withholding obligations from vesting restricted stock awards. Following the sale, Ainscow directly holds 2,248,441 shares of ASP Isotopes common stock.
ASP Isotopes Inc. (ASPI) announced it is hosting its inaugural Capital Markets Day in London, providing an operational and strategic update across nuclear medicine, electronics, helium and LNG, and nuclear fuels. Management highlights that the past 12 months marked a shift from development into early commercialization in several businesses.
The company plans to discuss target milestones for the next 12 months, including expected revenue growth from initial liquid helium production as Phase 1 of the Virginia Gas Project is completed, continued growth of its radiopharmacies, and first commercial shipments from its stable isotope division. These developments are presented as steps toward a stated EBITDA target of more than $300 million in 2031.
ASP Isotopes also continues to pursue separate public listings for Quantum Leap Energy and Noble Africa, and references proposed transactions involving ENDRA Life Sciences, Renergen and Noble Africa that will be detailed in a future Form S-4 and proxy statement. The company emphasizes extensive forward-looking and projections-related cautionary language and clarifies that EBITDA is a non-GAAP financial measure.
ASP Isotopes Inc. (ASPI) reported that executive officer Donald George Ainscow, EVP, General Counsel and Secretary, had 23,678 shares of common stock sold to cover tax obligations arising from an equity award. The company executed these shares under a mandatory sell-to-cover provision and stated the sale was not a discretionary trade by Ainscow. After these sales, he holds 776,322 shares of common stock directly.
ASP Isotopes Inc. (ASPI) reported that its chief operating officer, Robert Ainscow, sold 25,000 shares of common stock in an open market or private transaction under a Rule 10b5-1 trading plan. The weighted average sale price was about $3.91 per share, and he now directly holds 2,256,879 shares.
ASP Isotopes Inc. (ASPI) reported that Chairman and CEO Paul Elliot Mann sold a total of 251,275 shares of common stock in three transactions, all described as sell-to-cover sales effected under a Rule 10b5-1 trading plan adopted on December 30, 2025 to cover tax withholding obligations on quarterly vesting of a restricted stock award.
The reported weighted average prices were $3.91 for 83,758 shares (range $3.75–$3.96), $3.92 for 83,758 shares (range $3.875–$3.98), and $4.10 for 83,759 shares (range $3.925–$4.26). Post-transaction share holdings are not stated in this data.
ASP Isotopes Inc. (ASPI) received a Form 144 notice from Paul Elliot Mann covering a planned sale of 1,441,361 shares of common stock acquired as compensation through a restricted stock award on May 28, 2026 under an issuer equity incentive plan.
The planned sale’s Aggregate Market Value is stated as being based on the $3.78 closing market price on September 1, 2026. The remarks state that the sale includes shares to satisfy Mann’s income tax liabilities arising from the quarterly vesting of a 2,233,555‑share restricted stock award